ARTIVA PHARMACEUTICAL CO., LTD.

ARTIVA PHARMACEUTICAL CO., LTD. is a factory.

Company Introduction:

ARTIVA PHARMACEUTICAL CO., LTD. is a distinguished pharmaceutical manufacturing company located in Thailand. The company is dedicated to the research, development, production, and distribution of a diverse portfolio of high-quality pharmaceutical products. Operating with a steadfast commitment to innovation and excellence, ARTIVA PHARMACEUTICAL boasts modern manufacturing facilities that comply with stringent international Good Manufacturing Practice (GMP) standards. Their capabilities extend across various dosage forms, catering to both the domestic Thai market and international healthcare needs. The company emphasizes rigorous quality control throughout its processes and strives to contribute to better public health through the provision of safe, effective, and reliable medicines.

The provided search results primarily detail the products and pipeline of **Artiva Biotherapeutics, Inc.**, a clinical-stage biotechnology company focused on developing allogeneic natural killer (NK) cell-based therapies for cancer and autoimmune diseases. The information does not directly confirm the products sold or manufactured by a company specifically named "ARTIVA PHARMACEUTICAL CO., LTD." in Thailand.

However, assuming the intent of the question is to inquire about the therapies developed by the entity with the name "Artiva" in the context of pharmaceuticals/biotechnology, the products in their pipeline are:

* **AlloNK (AB-101):** An allogeneic, non-genetically modified, cryopreserved natural killer (NK) cell therapy.

* **Therapeutic Focus:** Being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) for conditions such as:

* Non-Hodgkin Lymphoma (NHL)

* Autoimmune diseases (e.g., Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Sjögren's Disease, Myositis, Systemic Sclerosis).

* **AB-201:** An allogeneic anti-HER2 CAR-NK cell product candidate.

* **Therapeutic Focus:** Solid tumors (e.g., advanced HER2+ solid tumors like Breast Cancer, Gastric Cancer).

* **AB-205:** An allogeneic anti-CD5 CAR-NK cell product candidate.

* **Therapeutic Focus:** T-cell lymphoma and leukemia.

These are investigational product candidates in clinical development.